{"id":"https://openalex.org/W2592048897","doi":"https://doi.org/10.1016/j.toxlet.2015.08.803","title":"Applying early discovery safety science to eliminate chemical toxicity and improve the pre-clinical efficacy of focal adhesion kinase inhibitors","display_name":"Applying early discovery safety science to eliminate chemical toxicity and improve the pre-clinical efficacy of focal adhesion kinase inhibitors","publication_year":2015,"publication_date":"2015-09-29","ids":{"openalex":"https://openalex.org/W2592048897","doi":"https://doi.org/10.1016/j.toxlet.2015.08.803","mag":"2592048897"},"language":"en","primary_location":{"id":"doi:10.1016/j.toxlet.2015.08.803","doi":"https://doi.org/10.1016/j.toxlet.2015.08.803","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.toxlet.2015.08.803","pdf_url":null,"source":{"id":"https://openalex.org/S205878144","display_name":"Toxicology Letters","issn_l":"0378-4274","issn":["0378-4274","1879-3169"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Toxicology Letters","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5034093381","display_name":"Mark J. Anderton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":true,"raw_author_name":"M. Anderton","raw_affiliation_strings":["AstraZeneca, Drug Safety & Metabolism, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Drug Safety & Metabolism, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5109794224","display_name":"S. Ashton","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"S. Ashton","raw_affiliation_strings":["AstraZeneca, Oncology iMED, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Oncology iMED, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068952265","display_name":"Bernard C. Barlaam","orcid":"https://orcid.org/0000-0002-0904-7556","observed_orcids":["https://orcid.org/0000-0002-0904-7556"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"B. Barlaam","raw_affiliation_strings":["AstraZeneca, Oncology iMED, Cambridge, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Oncology iMED, Cambridge, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"middle","author":{"id":null,"display_name":"C. Jones","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C. Jones","raw_affiliation_strings":["AstraZeneca, Oncology iMED, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Oncology iMED, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5091112024","display_name":"Corbin D. Jones","orcid":"https://orcid.org/0000-0001-7281-7130","observed_orcids":["https://orcid.org/0000-0001-7281-7130"]},"institutions":[{"id":"https://openalex.org/I105036370","display_name":"AstraZeneca (United Kingdom)","ror":"https://ror.org/04r9x1a08","country_code":"GB","type":"company","lineage":["https://openalex.org/I105036370"]}],"countries":["GB"],"is_corresponding":false,"raw_author_name":"C. Jones","raw_affiliation_strings":["AstraZeneca, Oncology iMED, Cheshire, United Kingdom"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"AstraZeneca, Oncology iMED, Cheshire, United Kingdom","institution_ids":["https://openalex.org/I105036370"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5034093381"],"corresponding_institution_ids":["https://openalex.org/I105036370"],"apc_list":{"value":4270,"currency":"USD","value_usd":4270},"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.34587875,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"238","issue":"2","first_page":"S279","last_page":"S279"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10945","display_name":"Lysosomal Storage Disorders Research","score":0.7221999764442444,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10945","display_name":"Lysosomal Storage Disorders Research","score":0.7221999764442444,"subfield":{"id":"https://openalex.org/subfields/2716","display_name":"Genetics (clinical)"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11308","display_name":"Sphingolipid Metabolism and Signaling","score":0.25589999556541443,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12281","display_name":"Animal testing and alternatives","score":0.0010999999940395355,"subfield":{"id":"https://openalex.org/subfields/3404","display_name":"Small Animals"},"field":{"id":"https://openalex.org/fields/34","display_name":"Veterinary"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/farber-disease","display_name":"Farber disease","score":0.9190000295639038},{"id":"https://openalex.org/keywords/asah1","display_name":"ASAH1","score":0.8169999718666077},{"id":"https://openalex.org/keywords/acid-ceramidase","display_name":"acid ceramidase","score":0.9929999709129333},{"id":"https://openalex.org/keywords/splice-site-variant","display_name":"splice site mutation","score":0.7400000095367432},{"id":"https://openalex.org/keywords/exon-skipping","display_name":"exon skipping","score":0.6899999976158142},{"id":"https://openalex.org/keywords/compound-heterozygosity","display_name":"compound heterozygosity","score":0.8659999966621399},{"id":"https://openalex.org/keywords/lysosomal-storage-disorders","display_name":"lysosomal storage disease","score":0.6759999990463257},{"id":"https://openalex.org/keywords/ceramide-metabolism","display_name":"ceramide metabolism","score":0.5170000195503235},{"id":"https://openalex.org/keywords/genotype-phenotype-correlation","display_name":"genotype-phenotype correlation","score":0.7179999947547913}],"concepts":[{"id":"https://openalex.org/C12125453","wikidata":"https://www.wikidata.org/wiki/Q5156837","display_name":"Compound heterozygosity","level":4,"score":0.655007004737854},{"id":"https://openalex.org/C2778776201","wikidata":"https://www.wikidata.org/wiki/Q3474283","display_name":"Exon skipping","level":5,"score":0.6524220108985901},{"id":"https://openalex.org/C36823959","wikidata":"https://www.wikidata.org/wiki/Q373027","display_name":"Exon","level":3,"score":0.6192466616630554},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.5659812688827515},{"id":"https://openalex.org/C501734568","wikidata":"https://www.wikidata.org/wiki/Q42918","display_name":"Mutation","level":3,"score":0.5377792119979858},{"id":"https://openalex.org/C127716648","wikidata":"https://www.wikidata.org/wiki/Q104053","display_name":"Phenotype","level":3,"score":0.4964633584022522},{"id":"https://openalex.org/C153911025","wikidata":"https://www.wikidata.org/wiki/Q7202","display_name":"Molecular biology","level":1,"score":0.4748647212982178},{"id":"https://openalex.org/C17757408","wikidata":"https://www.wikidata.org/wiki/Q4135516","display_name":"genomic DNA","level":3,"score":0.4676016867160797},{"id":"https://openalex.org/C54355233","wikidata":"https://www.wikidata.org/wiki/Q7162","display_name":"Genetics","level":1,"score":0.4645497500896454},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.453457772731781},{"id":"https://openalex.org/C176944494","wikidata":"https://www.wikidata.org/wiki/Q1415380","display_name":"Point mutation","level":4,"score":0.44765859842300415},{"id":"https://openalex.org/C194583182","wikidata":"https://www.wikidata.org/wiki/Q21114084","display_name":"Alternative splicing","level":4,"score":0.1448960304260254}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1016/j.toxlet.2015.08.803","doi":"https://doi.org/10.1016/j.toxlet.2015.08.803","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.toxlet.2015.08.803","pdf_url":null,"source":{"id":"https://openalex.org/S205878144","display_name":"Toxicology Letters","issn_l":"0378-4274","issn":["0378-4274","1879-3169"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Toxicology Letters","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9476000070571899}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W1980524423","https://openalex.org/W1988475564","https://openalex.org/W120197159","https://openalex.org/W2058884692","https://openalex.org/W4385720420","https://openalex.org/W2486335192","https://openalex.org/W2478215267","https://openalex.org/W3031775517","https://openalex.org/W2892334796","https://openalex.org/W2162987761"],"abstract_inverted_index":null,"counts_by_year":[],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2017-03-16T00:00:00"}